Kerschbaumer, Andreas http://orcid.org/0000-0002-6685-8873
Smolen, Josef S. http://orcid.org/0000-0002-4302-8877
Herkner, Harald http://orcid.org/0000-0003-1329-6149
Stefanova, Tijen
Chwala, Eva http://orcid.org/0000-0001-7686-5535
Aletaha, Daniel http://orcid.org/0000-0003-2108-0030
Article History
Received: 19 September 2019
Accepted: 11 March 2020
First Online: 20 April 2020
Competing interests
: A.K. has received consulting or lecture fees from Bristol-Myers Squibb, Celgene, Eli-Lilly, Merck Sharp and Dohme and Pfizer and non-financial support from Gilead; J.S.S. received grants to his institution from Abbvie, AstraZeneca, Janssen, Lilly, Merck Sharpe & Dohme, Pfizer and Roche and provided expert advice for, or had symposia speaking engagements with, AbbVie, Amgen, AstraZeneca, Astro, Bristol-Myers Squibb, Celgene, Celltrion, Chugai, Gilead, Glaxo, ILTOO Pharma, Janssen, Lilly, Merck Sharp & Dohme, Novartis-Sandoz, Pfizer, Roche, Samsung, Sanofi and UCB; H.H. has no financial relationship to disclose and is Co-ordinating Editor of the Cochrane EC Group; T.S. has no financial relationship to disclose; E.C. has no financial relationship to disclose; D.A. has received grants from AbbVie, Novartis, Roche and SoBi, consulting and lecture fees from Abbvie, Amgen, Celgene, Gilead, Galapagos, Lilly, Merck Sharpe & Dohme, Novartis, Pfizer, Roche, Sandoz and Sanofi/Genzyme.